From the Department of Neurology (O.Y.B., J.-W.C., M.J.L., W.-K.S.), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; Department of Neurology and Institute of Health Science (S.-K.K.), Gyeongsang National University College of Medicine, Jinju; Department of Neurology (S.J.K.), Hana General Hospital, Cheongju; Department of Neurology (J.H.), Kyungpook National University Chilgok Hospital, Daegu; Department of Neurology (Y.S.H.), Wonkwang University, School of Medicine, Iksan; Department of Neurology (S.M.S.), Pusan National University Hospital; Department of Neurology (E.-G.K.), Busan Paik Hospital, Inje University; Department of Neurology (S.-I.S.), Keimyung University School of Medicine, Daegu; and Department of Neurology (M.-K.H.), Seoul National University Bundang Hospital, Seongnam, Korea.
Neurology. 2019 Nov 19;93(21):e1955-e1963. doi: 10.1212/WNL.0000000000008520. Epub 2019 Oct 23.
To evaluate the safety and efficacy of induced hypertension in patients with acute ischemic stroke.
In this multicenter randomized clinical trial, patients with acute noncardioembolic ischemic stroke within 24 hours of onset who were ineligible for revascularization therapy and those with progressive stroke during hospitalization were randomly assigned (1:1) to the control and intervention groups. In the intervention group, phenylephrine was administered intravenously to increase systolic blood pressure (SBP) up to 200 mm Hg. The primary efficacy endpoint was early neurologic improvement (reduction in NIH Stroke Scale [NIHSS] score of ≥2 points during the first 7 days). The secondary efficacy endpoint was a modified Rankin Scale score of 0 to 2 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage/edema, myocardial infarction, and death.
In the modified intention-to-treat analyses, 76 and 77 patients were included in the intervention and control groups, respectively. After adjustment for age and initial stroke severity, induced hypertension increased the occurrence of the primary (odds ratio 2.49, 95% confidence interval [CI] 1.25-4.96, = 0.010) and secondary (odds ratio 2.97, 95% CI 1.32-6.68, = 0.009) efficacy endpoints. Sixty-seven (88.2%) patients of the intervention group exhibited improvements in NIHSS scores of ≥2 points during induced hypertension (mean SBP 179·7 ± 19.1 mm Hg). Safety outcomes did not significantly differ between groups.
Among patients with noncardioembolic stroke who were ineligible for revascularization therapy and those with progressive stroke, phenylephrine-induced hypertension was safe and resulted in early neurologic improvement and long-term functional independence.
NCT01600235.
This study provides Class III evidence that for patients with acute ischemic stroke, therapeutic-induced hypertension increases the probability of early neurologic improvement.
评估诱导高血压在急性缺血性脑卒中患者中的安全性和疗效。
这是一项多中心随机临床试验,纳入发病 24 小时内不适合血管再通治疗的急性非心源性缺血性脑卒中患者和住院期间进展性脑卒中患者,按 1:1 比例随机分配至对照组和干预组。在干预组中,静脉给予去氧肾上腺素将收缩压(SBP)升高至 200mmHg。主要疗效终点为早期神经功能改善(发病后第 1 天至第 7 天 NIHSS 评分降低≥2 分)。次要疗效终点为 90 天时改良 Rankin 量表评分为 0 至 2 分。安全性结局包括症状性颅内出血/水肿、心肌梗死和死亡。
在改良意向治疗分析中,干预组和对照组分别纳入 76 例和 77 例患者。调整年龄和初始卒中严重程度后,诱导高血压增加了主要(优势比 2.49,95%置信区间[CI]1.25-4.96, = 0.010)和次要(优势比 2.97,95%CI1.32-6.68, = 0.009)疗效终点的发生。在诱导高血压期间,干预组 67 例(88.2%)患者 NIHSS 评分改善≥2 分(平均 SBP 179·7±19.1mmHg)。两组安全性结局无显著差异。
对于不适合血管再通治疗的非心源性卒中患者和进展性卒中患者,去氧肾上腺素诱导高血压是安全的,可带来早期神经功能改善和长期功能独立性。
NCT01600235。
本研究提供 III 级证据表明,对于急性缺血性脑卒中患者,治疗性诱导高血压增加早期神经功能改善的可能性。